Abstract
Introduction
The term "therapy-related myeloid neoplasms" (t-MNs), proposed in the World Health Organization 2008 classification and recognized by the 2016 revision, defines a distinct category that includes patients who develop myeloid neoplasms after therapy with cytostatic agents and/or radiation therapy [1, 2] . t-MNs are further subdivided into therapy-related myelodysplastic syndromes (t-MDS) and therapy-related acute myeloid leukemia (t-AML). The clinical evolution is progressive from t-MDS to t-AML and is characterized by resistance to the conventional therapy used for de novo acute leukemia [3] . The family history should be investigated especially regarding cancer susceptibility [4] .
The WHO criteria (2008, 2016) for the diagnosis of t-MNs are based on: a) patient history of anterior exposure to cytotoxic agents or radiation, b) laboratory tests related to MDS and AML (bone marrow blasts < 20% = MDS; bone marrow blasts ≥ 20% = AML), c) cytogenetic and molecular abnormalities relevant to therapy and outcome [1, 2] .
t-MNs are a direct consequence of mutational events induced by therapy with cytostatic agents used for the treatment of the primary neoplasm [4] . Some individuals may have an inherited predisposition due to gene polymorphisms that affect drug metabolism or DNA repair mechanisms [3] . Mutations in proto-oncogenes have been identified in a number of t-MNs cases [5] .
t-MNs have been acknowledged as clinical syndromes that arise as a late complication of cytotoxic therapy [1, 3] . The latency period between the diagnosis of the primary neoplasm and t-MNs varies from between a couple of months to years and depends on the cumulative dose, dose-intensity and the type of preceding chemotherapy/radiation therapy [6] . There are two subcategories of t-MNs. The most frequent type of t-MN arises 5-10 year after exposure to alkylating agents and/or radiation and was initially associated with unbalanced genetic anomalies, usually involving chromosomes 5 and/or 7. A second category of t-MNs appears after a latency period of 1-5 years, after therapy with topoisomerase II inhibitors (etoposide, doxorubicin, mitoxantrone, idarubicin) and has been tied to the presence of balanced chromosomal translocations implicating 11q23 (MLL), 21q22 (RUNX1). In the WHO classification (2008, 2016) t-MNs form a single entity no longer dependent on the therapeutic agents.
t-MNs have been more often associated with treatment of solid tumors and malignant lymphomas and less with the treatment of acute leukemia [6, 7] .
Acute promyelocytic leukemia (APL) is a subtype of AML characterized by a particular morphology of the leukemic blasts (abnormal promyelocytes), a life threatening hemorrhagic syndrome caused by hyperfibrinolysis, disseminated intravascular coagulation (DIC) and thrombocytopenia, a characteristic cytogenetic abnormality: translocation (15;17) that leads to the fusion of the promyelocytic leukemia gene (PML) and the retinoic acid alpha receptor gene (RARA) resulting in the PML/RARA protein (marker of the disease). APL presents a particular sensitivity to the differentiating effect of alltrans-retinoic acid (ATRA) and to the apoptotic effect of arsenic trioxide (ATO) by targeting and inducting differentiation of leukemia initiating cells (LIC) [8, 9] . New data supports the view that the main mechanism of action of ATRA and ATO in eliminating leukemia initiating cells is by degrading the PML-RARA gene fusion product [10] . In the 2016 WHO revision, in order to highlight the importance of the PML/RARA fusion -that may be cryptic and can be the result of complex cytogenetic rearrangements different from t(15;17) (q24.1 q21.2) -APL with these particular abnormalities has been renamed APL with PML-RARA [2] .
By introducing the combination regimen (ATRA + anthracycline-based chemotherapy) and ATRA+ATO ("chemotherapy free" regimen) as front line treatment, the prognosis of APL has changed radically. APL has been transformed from a rapidly fatal disease to a type of "curable" leukemia [8, 11] . Treatment based on ATRA + anthracycline (idarubicin) -AIDA protocol -introduced through GIMEMA and PETHEMA and adapted to risk categories -is widely in use and has allowed an increase in the survival rates [12, 13, 14, 15] . The analysis of the AIDA study has shown an increase in the 6-year overall survival (OS) of 87.4% and a disease free survival (DFS) of 85.6% and cumulative incidence of relapse (CIR) 10.7% [14] . An analysis of an ATRA + ATO trial set between 2013 and 2016 has shown a 30,5-36 months OS of 93%-99,1%, event-free survival (EFS) 91%-98%, cumulative incidence of relapse (CIR) 1-1,1% [16, 17, 18] . The shift to first-line therapy of ATRA + ATO (chemotherapy free) still poses ATO related problems: dose calculation, induction and consolidation regimens, the cost of the drug, long term toxicity (neurologic effects, liver damage), ease of administration (advantages of a drug that may be administered orally as opposed to intravenously).
In the last couple of years, in the specialty literature, there have been several case reports of t-MNs after successful treatment for APL with regimens including ATRA + anthracycline or ATRA + ATO [7, 19, 20] . t-MDS and t-AML after CR of APL have become an emerging problem [21] .
t-MNs in APL (t-MDS/t-AML) are treatment resistant and a limiting factor in terms of favorable outcome of this particular type of leukemia. t-MNs (t-MDS/t-AML) must be distinguished from relapses which may lead to a new complete remission through the use of ATO ± auto/allogeneic stem-cell transplantation. The molecular biology tests: RT-PCR positive for the PML/RARA bcr2 isoform, negative for FLT3 ITD, CBFb -MYH11, MLL -AF9, NPM1, E2A-PBX1, MLL-AF4, SIS-TAL (Figure 3,4) .
Case report
Based on the morphology of the bone marrow aspirate a diagnosis of acute promyelocytic leukemia (M3 -FAB) was established and emergency treatment with oral all-trans-retinoic acid (ATRA) 45 mg/m 2 /day was initiated on the day of admission, before FISH demonstration of the translocation (15;17) or PML/RARA rearrangement. The patient was included in the "low risk" relapse category (Sanz 2000 score) based on a white blood cell count of <10,000/ µL and a platelet count over 40,000/µL, and the AIDA protocol was decided on in terms of treatment [22] .
Induction was started based on the following protocol: oral ATRA 45mg/m 2 /day and intravenous bolus idarubicin 12mg/m 2 on days 2, 4, 6, and 8 with close follow-up of clinical and biological parameters. Supportive treatment with platelet transfusion and fresh frozen plasma was required during induction in order to prevent consumption coagulopathy. The bacterial infections (cutaneous staphylococcal infection, acute tonsillitis) that occurred during post-chemotherapy cytopenia required treatment with antibiotics. Promyelocyte reversion was observed on the peripheral blood smear starting with the 12th day of ATRA treatment. During the third week of treatment, signs of the differentiation syndrome were evident: fever over 38ºC, weight gain and edema -symptoms that improved with dexamethasone 10 mg iv once every 12 hours for 5 days. abnormalities. At the follow-up in October 2015 the patient presented with good clinical condition and normal blood count (Hb 13,6 g/dl, WBC 3,400/µL: unsegmented 1%, segmented 70%, lymphocytes 20%, monocytes 8% and platelets 236,000/µL). Due to the decrease in WBC and platelet count, treatment with methotrexate and mercaptopurine was stopped in December 2015.
At follow-up on January 2016 she presented with good clinical condition, without signs of bleeding.
Laboratory tests revealed leukopenia with severe neutropenia (WBC 1,380/µL, absolute neutrophil count 552/µL, unsegmented 1%, segmented 39%, lymphocytes 42%, monocytes 18%), severe thrombocytopenia (platelets 41,000/µL), haemoglobin within normal ranges (Hb 12 g/dl). The peripheral blood smear showed hypogranular and agranular neutrophils. Bone marrow aspirate showed slightly reduced cellularity, increased fat percentage, ~ 16-18% myeloblasts-like agranular and granular blast cells, a decrease in the granulocytic series (45%), hypogranular and agranular neutrophils, normal erythroid series (25%) with normoblasts, mostly polychromatophilic and oxyphil cells, rare erythroblasts in mitosis, polymorphic megakariocytes (some with hyperlobuled nuclei and separate lobules and some small hypolobulated forms), decreased thrombocyte production. Conclusion: hypocellular bone marrow with myelodysplastic features (blast cells <20%) = RAEB-2 (WHO 2008); MDS-EB 2 (WHO 2016) ( Figure 5) .
Bone marrow biopsy showed left shift deviation; dysplastic small hypolobulated, megacaryocytes, erythroblasts with irregular nucleus (Figure 6 ). The cytogenetic study was repeated in January 2016, twenty metaphase with normal karyotype (46, XX). The molecular biology tests have not identified the PML/ RARA transcript, the FLT3-ITD mutation was undetectable.
The repeated absence of a molecular anomaly (PML/RARA transcript) and t (15;17) excluded the possibility of an APL relapse. The neutropenia and thrombocytopenia, the presence of dysplastic changes in both the granulocytic and megakariocytic series (hypogranular and agranular neutrophils, megakariocytes some with multiple, isolated nuclei and some without lobuled nuclei), as well as < 20% blast cells in the bone marrow led to the diagnosis of myelodysplastic syndrome (MDS) -refractory anemia with excess blasts 2 (MDS-EB2) (WHO 2016 classification). The bone marrow aspirate immunophenotyping established the phenotypic profile of an undifferentiated blast cell proliferation that does not express intracytoplasmatic myeloperoxidase (icMPO), but expresses myeloid surface markers in the context of myelodysplasia.
The diagnosis of therapy-related myelodysplastic syndrome was established (t-MDS -> RAEB-2) in a patient with complete molecular remission of APL after treatment with ATRA and anthracycline-based chemotherapy. The time interval from complete remission of APL to the diagnosis of t-MDS (RAEB-2) was 28 months. When the diagnosis of t-MN was established, the patient was on month 23 of maintenance therapy (ATRA + MTX + 6-MP). Calculating the risk category for t-MDS (RAEB-2), survival rate and risk of transformation to AML, the prognostic scores yielded the following results: a) International Prognostic Scoring System (IPSS): intermediate-2 risk group with a median survival of 1.2 years and a 25% risk of transformation to AML in 1.1 years; b)WHO-classification based Prognostic Scoring System (WPSS score): 3 (high risk) with a median survival of 2.2 years and a risk of transformation to AML of 0.54. This is the case of a young patient (36 years old), with a good performance status (KPS 90-100%), without comorbidities, with a diagnosis Bone marrow aspirate showed slightly decreased cellularity, 3-4% blast cells (myeloblasts, monocytoid blasts), decrease of the granulocytic series, with maturation: hypogranular and agranular neutrophils, increase of the erythroid series (39%), megakaryocytes present. On June 2016, the patient is admitted to the Departament of Bone Marrow Transplantation Fundeni Clinical Institute. The patient's data on evaluation before allo-HSCT: 36 year old, female patient, Karnofsky Performance Status 100 %, with complete remission after AML chemotherapy with 3-4% blast cells in the bone marrow aspirate. The cytogenetic study revealed normal karyotype. The time from t-MDS diagnosis to transplant was 6 months. CMV status was negative. The donor's data mentioned 10/10 HLA matched unrelated donor, male, 30 years old, 0 negative group (patient: B positive), CMV negative. Data related to the transplant procedure: myeloablative conditioning regimen (Bu/Cy); GVHD prophylaxis with cyclosporine, MTX + ATG started on June 2016. Posttransplant status with severe mucositis, E. coli sepsis due to persistent agranulocytosis, severe thrombocytopenia, severe anemia with transfusion incidents. Despite supportive care (broad spectrum antibiotics, red blood cell and platelets transfusions, electrolyte imbalance correction) the patient's status declined progressively and death occurred on day 9 after transplantation ( Table 1) .
Discussions
During the last couple of years multiple reports on treatment-related neoplasia have been published: t-MDS and t-AML in patients with complete remission after APL treated by standard protocol with ATRA and anthracyclinebased chemotherapy (AIDA) [7, 19, 20, 21, 23, 24] .
The incidence of t-MN in APL reported in studies varies: 0.97% (6 of 617 patients) [24] , 6.5% (3 of 46 patients) [21] , 10.2% (11 of 108 patients) [19] . Montesinos et al. (2010) reported 17 t-MNs diagnosed in a number of 918 patients with APL with complete remission. Of the 17 t-MNs cases: 10 were t-MDS (bone marrow blast cells < 20%) and 7 were AML (bone marrow blast cells > 20%). The cumulative incidence in a time frame of 6 years: 2.2%. 6-year incidence based on risk group: low, intermediary and high were of 5.2%, 2.1% and 0%. Another 14 patients developed a series of solid tumors (colorectal carcinoma (n=4); carcinoma of the lung (n=2), breast (n=2), prostate (n=1), kidney (n=1), thyroid (n=1), pancreas (n=1), cervix (n=1), non-Hodgkin lymphoma (n=1).
The higher incidence of APL in younger patients (starting with the second decade of life) is well known, and decreases after the age of 60 [25, 26, 27] . For patients who develop t-MNs during the CR of APL, the median age at APL diagnosis was 50 years old (18-68 years) [7] and 52 years (18-86 years) [19] . In the PETHEMA study, there was a higher prevalence among female patients (11F/6M) and a higher male prevalence in the Japanese study (3F/9M) [7, 19] .
The time interval between APL diagnosis and the development of a t-MN was 43-46 months in the PETHEMA study. Three of the 17 cases of t-MNs emerged during maintenance therapy [7] .
Cases of t-MNs have been reported in the second and third CR of APL [21] .
A Japanese study observed the clinical and hematopoietic differences between t-MNs in CR of APL and relapses [19] . In a lot of 108 patients with APL in their first complete remission there were 11 (10.2%) who developed t-MNs (t-MDS and t-AML) and 10 (9.3%) who relapsed. The median follow-up period: 8.6 years (1.7-16.3 years). The median time from the diagnosis of ALP to t-MDS (RCMD) was 2.3 years (1.6-3 years) and from the diagnosis of APL to t-MDS/t-AML: 3.3 years (1.0-9.7 years) and for APL relapse: 2.6 years (0.6-10.1 years). By comparing the hematologic data from 11 t-MN cases and 10 relapse cases, the authors noted a statistically significant difference in terms of the white blood cell counts at APL diagnosis. t-MNs patients had a lower WBC (leucocytes≤ 4.500/µL) as opposed to those with relapse (leucocytes > 4.500/µL) (P=0,048). The t-MNs cases were PML/RARA-, CD34+, HLA-DR+ and the RUNX1/AML1 mutation was reported in 4 cases. Overall survival measured from the initiation of chemotherapy was significantly lower in patients with t-MNs than in those with relapse (P = 0.022)
In t-MNs after APL frequent karyotype abnormalities with poor outcomes have been identified: partial or complete deletions of An analysis of the cytogenetic alterations in 14 of the 17 patients in the PETHEMA study has shown: partial or complete deletions of the chromosomes 5 and 7 in 9 patients; 11q23/ MLL rearrangements in 3 patients; complex karyotype (≥ 3 abnormalities) in 6 patients; normal karyotype in 1 patient; monosomal karyotype in 6 patients. Translocations involving MLL/11q23, that typically correlates with topoisomerase II inhibitor therapy was encountered less frequently (3 cases) than -5/ del (5q) and -7/del (7q) (9 cases). The partial or complete deletion of chromosomes 5 and 7 was associated in some studies with prior exposure to alkylating agents -not applicable to the studied APL patients. The ELN group [24] described 6 patients with t-MDS in CR of APL with abnormalities in chromosomes 5 and 7, despite not having received treatment with alkylating agents or radiotherapy. The observations made by researchers of the PETHEMA and the ELN group support the changes recently added by the WHO (2008, 2016) claiming that t-MNs can no longer be divided into 2 subcategories: alkylating agents related and topoisomerase II related. Today t-MNs are classified as a single entity.
In analyzing the 11 t-MDS/t-AML the Japanese group (Imagawa et al.) found: complete deletions of 7/-7, translocations implicating 21q 22 (RUNX1) and 11q 23 (MLL). PML-RARA negative t-MNs develop from a "receptive" hematopoietic stem cell or a normal hematopoietic progenitor cell through the accumulation of genic abnormalities induced by chemotherapy, including the RUNX1 mutation [19] . In terms of molecular biology, Imagawa et al. found mutations involving RUNX1 (4 cases) and CEPBA (1 case) -mutations that were not present at APL diagnosis. 3 out of 4 RUNX1 mutations were correlated with monosomy 7. One case with a RUNX1 mutation also acquired NRAS.
The majority of t-MN cases (t-MDS/t-AML) were either low or intermediate risk APL. At APL diagnosis, the risk score for relapse (Sanz score) allows for a better choice regarding treatment, based on WBC and platelet counts. Patients at low risk receive a lower total dose of anthracyclines (idarubicin, mitoxantron) that those with high risk [15, 22] . The data from literature reveals a higher risk of developing t-MNs in patients with a lower risk of relapse. Montesinos & al. [7] mention that out of 17 patients with t-MNs, 8 were low risk (136 total patients) and 9 were intermediary risk (from a total of 280 patients). Imagawa & al. [19] remark that 9 out of 11 patients with t-MNs were low risk and 2 were high risk. These papers do not support the potential correlation between dose-intensity of topoisomerase II inhibitors and a higher prevalence of t-MNs in low risk patients who are generally treated with lower dose anthracycline regimens. The transition toward chemotherapyfree first-line treatment based on the association of ATRA + ATO in newly diagnosed low and intermediary risk cases comes as a solution in trying to lower the incidence of t-MNs [16, 18] .
Maintenance therapy with methotrexate and mercaptopurine may have a potential role in the development of t-MNs -as proven in children with acute lymphoblastic leukemia [28] . It is known that maintenance therapy reduces the risk of relapse. However, it increases incidence of t-MNs in APL. By using etoposide (VP-16) in the maintenance regimen, the incidence of t-MNs increased to 10.2% in the Japanese study [19] . PCR monitoring of the PML/RARA transcript in CR of APL with low risk may be a substitute for maintenance therapy. Prevention of t-MNs is very important. t-MNs in APL represents a limiting factor in the outcome of a now curable form of leukemia.
t-MNs that develop over CR of APL have a poor prognosis. Cytogenetic abnormalities associated with poor outcomes (monosomal karyotype, partial or complete chromosome 5 or 7 deletions, complete karyotype) found in the majority of cases predict aggressive clinical evolution [7] .
In terms of risk factors, through multivariate analysis, the PETHEMA group has highlighted the following characteristics associated with t-MN development: older age (35 years as the most significant cutoff) (p=0.008); low risk of relapse (p=0.008); high platelet count (with 40 x 10^9/l as the most significant cutoff) (p=0.03). The multivariate analysis identified independent prognosis factors for t-MNs: age (hazard ratio=8.89; p=0.001) and relapse score(hazard ratio=0.34; p=0.005) [7] .
The survival of t-MN patients is poor even in cases with timely diagnosis and treatment. t-MN patients are excluded for MDS/AML front line treatment trials. The PETHEMA analysis [7] involving the 17 cases of t-MNs (diagnosed among 918 APL patients in CR) may give information of prognosis and treatment. Eight of the 10 cases of t-MDS progressed to acute leukemia in 9 months after diagnosis (4-19 months) and 9 out of 10 patients deceased after a median period of 10 months (5-32 months). One patient with t-MDS (AREB1) developed acute "B" lymphoblastic leukemia (CD45-, TDT+, CD79+, CD34-, CD19+, CD10+, no myeloid markers), was treated and died after 32 month with treatment-resistant disease. Four patients with t-MDS who developed AML and a patient with t-MDS (RAEB-1) received intensive chemotherapy followed by allogeneic hematopoietic stem-cell transplantation (allo-HSCT), with only one of the patients still alive at 30 months. Out of the 7 t-AML cases, one patient received only supportive care while 6 others received intensive chemotherapy. Three of the patients who achieved CR underwent allo-HSCT but only one survived at 39 months. Five patients died after a median time of 10 months from the second diagnosis (2-12 months). Overall survival (OS) 2 years after the diagnosis of t-MN was 19% with a median OS of 10 months [7] . These patients' low hematopoietic stem cell reserves make standard AML therapy difficult. Drug resistance of the new malignant clone is another cause of treatment failure. Often, even cytogenetic and molecular remissions are shortened. Allogeneic stem-cell transplantation is most likely the only potentially curative treatment [29] . After analyzing the results of the EBMT group between 1981-2006, Kroger determined that only a third of the 461 patients with t-MNs, were "cured" after receiving allo-HSCT. In the multivariate analysis younger patients (< 40 years old) with normal karyotypes who were transplanted during the first CR had the most favorable prognosis. Some case series describe 20-30% survival at 3 years after allo-HSCT in t-MNs.
Monitoring the CR in a patient with APL is done by detecting the PML/RARA transcript in the bone marrow or peripheral blood samples. The reappearance of the PML/RARA transcript is typical of molecular relapse and precedes hematologic relapse. The PETHEMA group suggested that patients treated during molecular relapse have more favorable outcomes than those treated after hematologic relapse. The timely detection of the PML/RARA transcripts and ATO treatment initiation may lead to a new CR [30, 31] .
Patients who develop t-MNs during the CR of APL are PML/RARA negative. Cytogenetic analysis show no evidence of t (15;17) . Some cytogenetic aberrations may be present (complete or partial deletions of the chromosomes 5 and 7, complex karyotype, translocations involving 11q23 (MLL) or 21q23 (RUNX1), blast cells with a different phenotype that promyelocytic blast cells at the diagnosis of APL.
During the follow-up of a patient in remission at low/intermediate risk of relapse, a closer look must be taken at the changes of the blood count (cytopenia, peripheral blood anomalies: macrocytosis, hypogranular or agranular neutrophils). In such cases obtaining a bone marrow sample is in order; karyotyping may find signs of myeloid neoplasia (MDS, AML).
Conclusion
NM-t in RC of APL are a distinct problem in terms of follow-up and differential diagnosis with disease relapse. Good survival rates occur in patients who achieve a new CR and are eligible for allo-HSCT. The possibility of developing a treatment-related myeloid neoplasm accentuates the importance of long term surveillance of APL survivors.
Conflicts of interest
The authors declare that they have no conflict of interest. 
Abbrevations

